Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Lorimer

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Elife|July 25, 2024
Modeling glioblastomaIan Lorimer
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 28, 2023
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapyBoaz Wong, Anabel Bergeron, Glib Maznyi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glandsMark Agulnik, Ezra W E Cohen, Roger B Cohen, et al.
The New England Journal of Medicine|July 15, 2005
Erlotinib in lung cancer - molecular and clinical predictors of outcomeMing-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 studyGlenwood D Goss, Chris O'Callaghan, Ian Lorimer, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Elife|July 25, 2024
Modeling glioblastomaIan Lorimer
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 28, 2023
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, sensitizes cancer cells to VSVΔ51 oncolytic virotherapyBoaz Wong, Anabel Bergeron, Glib Maznyi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 2007
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glandsMark Agulnik, Ezra W E Cohen, Roger B Cohen, et al.
The New England Journal of Medicine|July 15, 2005
Erlotinib in lung cancer - molecular and clinical predictors of outcomeMing-Sound Tsao, Akira Sakurada, Jean-Claude Cutz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 studyGlenwood D Goss, Chris O'Callaghan, Ian Lorimer, et al.
Pageof 1